Is Cingulate Inc. (CING) a Buy, Sell, or Hold?
Cingulate Inc.
NASDAQ:CING
$4.71 USD
$0.03 (0.64%)
- Volume
- 205.28K
- Average Volume
- 567.05K
- Market Capitalization
- $26.4M
- P/E Ratio
- -0.94
- Dividend Yield
- 0.00%
- Price Target
- $10.00
- Year High
- $11.89
- Year Low
- $3.16
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.55
| Source | Headline |
|---|---|
|
Cingulate Inc. (NASDAQ: CING) Added to Russell 3000E®
CEO Shane Schaffer: Inclusion Demonstrates Continued Growth and Enhanced Visibility Among Institutional Investors CEO Shane Schaffer: Inclusion Demonstrates Continued Growth and Enhanced Visibility Among Institutional Investors globenewswire.com - 2026-07-02 08:30:00 |
|
Cingulate Issued First U.S. Patent for Lead ADHD Asset CTx-1301
KANSAS CITY, Kan., June 16, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced the issuance of its first company-owned U.S. patent covering its lead asset, CTx-1301 (dexmethylphenidate HCl), for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). globenewswire.com - 2026-06-16 08:00:00 |
|
Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 1Q26
Dallas, Texas--(Newsfile Corp. - June 4, 2026) - Cingulate Inc. (NASDAQ: CING): Stonegate Capital Partners updates coverage on Cingulate Inc. (NASDAQ: CING). Cingulate's latest update shifts the near-term CTx-1301 setup from a PDUFA driven approval event to a CMC-driven resubmission process, while leaving the core product thesis intact based on the information disclosed. newsfilecorp.com - 2026-06-04 16:48:00 |
|
US FDA declines to approve Cingulate's ADHD drug
Cingulate said on Tuesday that the U.S. Food and Drug Administration declined to approve its drug to treat attention deficit hyperactivity disorder. reuters.com - 2026-06-02 08:08:19 |
|
Cingulate Receives Complete Response Letter from FDA for CTx-1301
No Clinical Safety or Efficacy Concerns Currently Identified Agency Feedback Primarily Focused on CMC-Related Requests Company Plans Prompt Response and Submission of Requested Information Company is Well Capitalized with Nearly $30 Million Cash on Hand KANSAS CITY, Kan., June 02, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform to develop a pipeline of next-generation products, today announced that the U.S. Food and Drug Administration (“FDA”) has issued a Complete Response Letter for its New Drug Application (“NDA”) for CTx-1301 (dexmethylphenidate HCl) for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). globenewswire.com - 2026-06-02 08:00:00 |
|
Cingulate Inc. Reports First Quarter 2026 Financial Results and Provides an Update of Commercial Readiness Efforts On Track for lead ADHD Asset CTx-1301
KANSAS CITY, Kan., May 14, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform to develop a pipeline of next-generation products, today reported financial results for the quarter ended March 31, 2026, and provided a corporate update. globenewswire.com - 2026-05-14 08:00:00 |
